Annual Report to the Nation on the Status of Cancer (2025)

# **Summary: Annual Report to the Nation on the Status of Cancer (2025)** The 2025 report shows a **continued, steady decline in U.S. cancer death rates** for men, women, and children from **2001 through 2022**, including the first two years of the COVID‑19 pandemic. ### **Key Findings** - **Cancer mortality continues to fall** across all major racial and ethnic groups from 2018 to 2022. - **Incidence trends diverge by sex:** - Among **men**, cancer incidence declined from 2001–2013 and then stabilized through 2021. - Among **women**, incidence increased slightly each year from 2003–2021 (except 2020). - **Lung cancer remains the biggest driver of mortality improvement**, with long‑term declines in both incidence and death rates. - **Obesity‑associated cancers are rising**, including breast, uterine, colorectal, pancreatic, kidney, and liver cancers. - **Breast cancer incidence is gradually increasing**, but mortality continues to decline. - **Pediatric and AYA cancer deaths continue to fall**, though the decline has recently slowed in adolescents and young adults. - **COVID‑19 impact:** - Cancer incidence dropped sharply in 2020 due to care disruptions, but **returned to expected levels by 2021**. - The decline was **consistent across states**, regardless of policy differences. - Findings underscore the importance of **maintaining access to care during public health emergencies**. --- # **Why This Matters for the Future of Cancer Diagnostics** The report highlights two converging realities: 1. **Mortality is falling because early detection and treatment are improving.** 2. **Incidence is rising in several high‑burden cancers**, especially those tied to obesity and aging populations. This creates a **critical market inflection point** for in‑vitro cancer testing—particularly **MCED**, **MRD**, and high‑sensitivity molecular assays that can detect recurrence or disease progression earlier than imaging. --- # **GRN IVD Consulting In‑Vitro Cancer Testing Market Report** ### *Your strategic guide to the next decade of oncology diagnostics* As cancer epidemiology shifts, diagnostics companies, investors, and hospital labs need clarity on: - **Which technologies will shape early detection and surveillance** - **How clinical algorithms are evolving across tumor types** - **Where regulatory and reimbursement signals are accelerating adoption** - **How MCED and MRD players are positioning competitively** The **GRN IVD Consulting In‑Vitro Cancer Testing Market Report** delivers: - Deep **competitive intelligence** across MCED, MRD, liquid biopsy, and advanced immunoassays - **Clinical‑algorithm mapping** aligned to real‑world oncology workflows - **Regulatory and payer‑signal tracking**, including Breakthrough Device designations and Medicare coverage trends - **Performance‑claim comparisons** to identify differentiation opportunities - **Strategic recommendations** for BD, portfolio planning, and market entry If the Annual Report to the Nation shows where cancer is heading, the GRN report shows how diagnostic companies can lead in that future.